PALO ALTO, January 15, 2015 – Depomed, Inc. (NASDAQ: DEPO) today announced that it has entered into a definitive agreement to acquire the U.S. rights to the NUCYNTA franchise from Janssen Pharmaceuticals, Inc. for $1.05 billion. The NUCYNTA franchise includes NUCYNTA® ER (tapentadol) extended release tablets indicated for the management of pain, and NUCYNTA® (tapentadol), an immediate release version of tapentadol. The deal will make NUCYNTA the flagship asset in Depomed’s growing portfolio of pain and neurology specialty pharmaceuticals.
Baker Botts represented Depomed in the acquisition.
Baker Botts Lawyers/Office Involved: John Martin (Partner, Palo Alto); Brian Lee (Partner, Palo Alto); Scott Mollett (Associate, Palo Alto); Clark Wilkes (Associate, Palo Alto); Don Lonczak (Partner, Washington); Paul Ragusa (Partner, New York); Jon Platt (Associate, Dallas); Luke Weedon (Partner, Dallas); Mark Johnson (Associate, Dallas)
ABOUT BAKER BOTTS L.L.P.
Baker Botts is an international law firm of more than 700 lawyers practicing throughout a network of 13 offices around the globe. Based on our experience and knowledge of our clients' industries, we are recognized as a leading firm in the energy, technology, and life sciences sectors. Since 1840, we have provided creative and effective legal solutions for our clients while demonstrating an unrelenting commitment to excellence. For more information, please visit bakerbotts.com.